核酸药物治疗肌萎缩侧索硬化的前景
本文综述了反义寡核苷酸治疗肌萎缩侧索硬化的现状与前景。Tofersen的I/II期研究显示鞘内给药使脑脊液SOD1水平降低36%;另2例突变SOD1患者接受AAV-microRNA治疗,其中1例尸检脊髓SOD1降低>90%。靶向FUS和C9orf72的反义寡核苷酸试验正在进行,靶向TDP-43调控因子或下游蛋白的策略也在开发中。
要点
- Tofersen鞘内给药使家族性SOD1突变ALS患者脑脊液SOD1降低36%。
- AAV递送靶向SOD1的microRNA在1例患者脊髓中实现>90%的SOD1降低。
- 靶向FUS和C9orf72的反义寡核苷酸临床试验正在进行中。
核心结论
- 核酸药物能够特异性干预ALS病理级联中的分子,拓展治疗靶点选择。
研究设计与样本
- 本文为综述,概述反义寡核苷酸治疗ALS的现状与前景,未报告系统检索范围。
主要发现
- Tofersen的I/II期研究治疗家族性SOD1突变ALS,鞘内给药使脑脊液SOD1水平降低36%。
- 2例突变SOD1患者接受AAV编码靶向SOD1的microRNA治疗,其中1例快速进展的A5V突变患者接受单次鞘内输注,16个月后死于呼吸骤停,尸检显示脊髓SOD1降低>90%。
- 靶向FUS和C9orf72的反义寡核苷酸治疗临床试验正在进行。
- 针对TDP-43病理,正在开发靶向TDP-43调控因子ataxin 2和下游蛋白stathmin 2的反义寡核苷酸策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nucleic acid therapeutics have been attracting attention as novel drug discovery modalities for intractable diseases, including amyotrophic lateral sclerosis. This review provides an overview of the current status and prospects of antisense oligonucleotide treatment for amyotrophic lateral sclerosis. Recently, the results of a phase I/II study using the antisense oligonucleotides Tofersen to treat familial amyotrophic lateral sclerosis with superoxide dismutase 1 mutation have been reported. Intrathecal Tofersen administration resulted in a 36% reduction in superoxide dismutase 1 level in the cerebrospinal fluid. Another report described 2 patients with mutant superoxide dismutase 1 treated with an adeno-associated virus encoding a microRNA targeting superoxide dismutase 1. The first patient, who possessed the fast progressive mutant A5V, received a single intrathecal infusion. Although the patient died of respiratory arrest 16 months after treatment, autopsy findings showed a reduction of >90% in superoxide dismutase 1 level in the spinal cord. Clinical trials on antisense oligonucleotide therapies targeting other major amyotrophic lateral sclerosis-causative genes, fused in sarcoma and chromosome 9 open reading frame 72, are ongoing. To attenuate the pathology of TDP-43, strategies targeting regulators of TDP-43 (ataxin 2) and proteins downstream of TDP-43 (stathmin 2) by antisense oligonucleotides are being developed. The advent of nucleic acid therapeutics has enabled to specifically attack the molecules in the amyotrophic lateral sclerosis pathological cascade, expanding the options for therapeutic targets. ANN NEUROL 2022;91:13-20.
引用
- Ito D. Promise of Nucleic Acid Therapeutics for Amyotrophic Lateral Sclerosis. Ann Neurol. 2021. PMID: 34704267. doi:10.1002/ana.26259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。